AR126215A1 - Proceso novedoso - Google Patents

Proceso novedoso

Info

Publication number
AR126215A1
AR126215A1 ARP220101651A ARP220101651A AR126215A1 AR 126215 A1 AR126215 A1 AR 126215A1 AR P220101651 A ARP220101651 A AR P220101651A AR P220101651 A ARP220101651 A AR P220101651A AR 126215 A1 AR126215 A1 AR 126215A1
Authority
AR
Argentina
Prior art keywords
hexahydro
ethyl
sulfonamide
carbamoyl
piperidine
Prior art date
Application number
ARP220101651A
Other languages
English (en)
Spanish (es)
Inventor
Paul Palguna Jetta Bharatha Mallesh Cinqualbre Josephine Eliette Franoise Mondire Rgis Jean G Fraser
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR126215A1 publication Critical patent/AR126215A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/98—Nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP220101651A 2021-06-23 2022-06-23 Proceso novedoso AR126215A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN202141028180 2021-06-23

Publications (1)

Publication Number Publication Date
AR126215A1 true AR126215A1 (es) 2023-09-27

Family

ID=82458485

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101651A AR126215A1 (es) 2021-06-23 2022-06-23 Proceso novedoso

Country Status (12)

Country Link
US (1) US20240150291A1 (cg-RX-API-DMAC7.html)
EP (1) EP4359385A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024524215A (cg-RX-API-DMAC7.html)
KR (1) KR20240024842A (cg-RX-API-DMAC7.html)
CN (1) CN118019727A (cg-RX-API-DMAC7.html)
AR (1) AR126215A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022300325A1 (cg-RX-API-DMAC7.html)
CA (1) CA3219597A1 (cg-RX-API-DMAC7.html)
IL (1) IL308071A (cg-RX-API-DMAC7.html)
MX (1) MX2023014547A (cg-RX-API-DMAC7.html)
TW (1) TW202317514A (cg-RX-API-DMAC7.html)
WO (1) WO2022268935A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240148839A (ko) * 2022-02-15 2024-10-11 에프. 호프만-라 로슈 아게 1,2,3,5,6,7-헥사히드로-s-인다센 유도체 제조를 위한 공정
EP4638422A1 (en) * 2022-12-23 2025-10-29 F. Hoffmann-La Roche AG Proccesses for the preparation of an nlrp3 inhibitor
WO2025036914A1 (en) 2023-08-16 2025-02-20 F. Hoffmann-La Roche Ag Process for the preparation of preparing 1-ethyl-n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)piperidine-4-sulfonamide
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3及glp-1a組合療法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA917435B (en) * 1990-09-26 1992-05-27 Takeda Chemical Industries Ltd Herbicides
CA2059450A1 (en) * 1991-01-24 1992-07-25 Nobuyuki Sakashita Subsituted pyridinesulfonamide compound or its salt, process for preparing the same, and herbicide containing the same
EP0981526B1 (en) * 1997-05-02 2004-02-25 Dr. Reddy's Laboratories Ltd. Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
DK1340757T3 (da) * 2000-11-16 2007-02-12 Sankyo Co 1-methylcarbapenemderivater
EP1403255A4 (en) * 2001-06-12 2005-04-06 Sumitomo Pharma RHO KINASE INHIBITORS
CN100360130C (zh) * 2002-04-18 2008-01-09 先灵公司 用作组胺h3拮抗剂的1-(4-哌啶基)苯并咪唑酮
EP1677783A2 (en) * 2003-10-08 2006-07-12 Nicholas Piramal India Limited Fibrinogen receptor antagonists and their use
DOP2006000009A (es) * 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
ZA200904857B (en) * 2007-02-22 2010-09-29 Merck Serono Sa Quinoxaline compounds and use thereof
US20120196889A1 (en) * 2009-02-25 2012-08-02 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
JP5898962B2 (ja) * 2012-01-11 2016-04-06 東京応化工業株式会社 レジスト組成物及びレジストパターン形成方法
WO2017095758A1 (en) * 2015-12-01 2017-06-08 Merck Sharp & Dohme Corp. Homobispiperidinyl derivatives as liver x receptor beta agonists, compositions, and their use
CN110914256A (zh) * 2017-07-07 2020-03-24 英夫拉索姆有限公司 新颖磺酰胺羧酰胺化合物
GB201712282D0 (en) * 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome
TW201910314A (zh) * 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
CN111902141A (zh) * 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
CR20200588A (es) * 2018-05-04 2021-06-24 Inflazome Ltd Compuestos novedosos
CR20210148A (es) * 2018-09-21 2021-05-18 Novartis Ag Compuestos de isoxazol carboxamida y usos de los mismos
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
GB201819083D0 (en) * 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
WO2020157069A1 (en) * 2019-01-28 2020-08-06 NodThera Limited Amino heterocyclic compounds and uses thereof
CN111393415B (zh) * 2020-04-30 2020-11-20 苏州信诺维医药科技有限公司 一种杂芳腈类化合物及其应用

Also Published As

Publication number Publication date
EP4359385A2 (en) 2024-05-01
US20240150291A1 (en) 2024-05-09
IL308071A (en) 2023-12-01
WO2022268935A2 (en) 2022-12-29
CN118019727A (zh) 2024-05-10
KR20240024842A (ko) 2024-02-26
MX2023014547A (es) 2024-04-29
AU2022300325A8 (en) 2023-11-16
JP2024524215A (ja) 2024-07-05
AU2022300325A1 (en) 2023-11-02
CA3219597A1 (en) 2022-12-29
TW202317514A (zh) 2023-05-01
WO2022268935A3 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
AR116753A1 (es) Proceso de preparación de un derivado de pirazolsulfonilamida
CO2023009368A2 (es) Cocristal de un inhibidor de cdk
AR128931A1 (es) Inhibidores del factor b del complemento y usos de los mismos
CR20250413A (es) Compuestos de pirido[4,3–d]pirimidina
CL2024001022A1 (es) Moléculas pequeñas para el tratamiento del cáncer
CO2026005655A2 (es) Inhibidor de pan-kras y uso del mismo en medicinas
AR128717A1 (es) Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2
MX2021011144A (es) Derivados de las benzodiazepinas como inhibidores del vsr.
FR2430939A1 (fr) Nouveaux derives d'acides (dl)-16-(phenoxy ou phenoxy substitue)-9-ceto- prostatrienoiques, leur procede de production et medicament les contenant
US20250066282A1 (en) Novel analogs of valproic acid and methods of medical treatment using the same
AR127247A1 (es) Inhibidores de cdk2 de ciclopentilpirazol
EP2722042A4 (en) INDANO DERIVATIVES, PHARMACEUTICALLY ALLOWED SALTS OR OPTICAL ISOMERS THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREFORE AS AN ACTIVE AGENT FOR THE PREVENTION OR TREATMENT OF VIRUS DISEASES
WO2022268935A3 (en) Process for the preparation of nlrp3 inhibitors
CO2025003090A2 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
CL2024003460A1 (es) Derivados de oxoindolinil amida para inhibir nlrp3 y usos de los mismos.
DOP2024000239A (es) Compuestos amido heteroaromáticos útiles en el tratamiento de enfermedades hepáticas
CO2025003099A2 (es) Compuestos para el tratamiento del cáncer
AR124036A1 (es) Una composición farmacéutica que comprende una sal farmacéuticamente aceptable de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propilo)amina, y un fármaco farmacéutico para la enfermedad del parkinson y usos de dicha composición
MX2025013370A (es) Inhibidores de moléculas pequeñas de glutaminasa
AR131735A1 (es) Agentes terapéuticos
UY39681A (es) Derivados de ciclobutilo 1,3–sustituidos y sus usos
AR128498A1 (es) Procesos novedosos
PY2067193A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
AR131692A1 (es) Formas cristalinas o sales de un compuesto deuterado
MX2022015532A (es) Inhibidores selectivos de hdac6 y usos de los mismos.